Background Community-acquired pneumonia (CAP) is the third-leading infectious cause of
death worldwide. The standard treatment of CAP has not changed for the past fifty years and …

Background Our aim was to evaluate the benefits and harms of adjunctive corticosteroids in
adults hospitalized with community-acquired pneumonia (CAP) using individual patient data …

Previous randomized controlled trials (RCTs) and meta-analyses evaluated the efficacy and
safety of adjunctive corticosteroids for community-acquired pneumonia (CAP). However, the …

Rationale: Some studies have shown a beneficial effect of corticosteroids in patients with
community-acquired pneumonia (CAP), possibly by diminishing local and systemic …

Background and objective Although the benefits of systemic corticosteroids in community‐
acquired pneumonia (CAP) are not clear, their use is frequent in clinical practice. We …

Objective: To review the evidence and recommendations for the use of adjunctive
corticosteroid therapy in community-acquired pneumonia (CAP). Data Sources: A literature …

BACKGROUND: Community-acquired pneumonia (CAP) is pneumonia acquired infectiously
from normal social contact as opposed to being acquired during hospitalization. CAP is a …

Background Community-acquired pneumonia (CAP) induces lung and systemic
inflammation, leading to high morbidity and mortality. We systematically reviewed the risks …

Community-acquired pneumonia (CAP) has a significant impact on public health in terms of
short-term and long-term morbidity and mortality. Irrespective of microbiological etiology, the …

Background The benefits and adverse effects of corticosteroids in the treatment of severe
community-acquired pneumonia (CAP) have not been well assessed. The aim of this …